

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	Release of Security Interest

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
Monarch Pharmaceuticals, Inc.		05/11/2010	CORPORATION: TENNESSEE

RECEIVING PARTY DATA

Name:	CREDIT SUISSE AG
Street Address:	11 Madison Avenue
Internal Address:	As Administrative Agent
City:	New York
State/Country:	NEW YORK
Postal Code:	10010
Entity Type:	Bank: SWITZERLAND

PROPERTY NUMBERS Total: 16

Property Type	Number	Word Mark
Registration Number:	2029430	ACCUDOSE
Registration Number:	3130490	ACCUDOSE
Registration Number:	0616775	CORTISPORIN
Registration Number:	2365721	CORTISPORIN TC
Registration Number:	0581264	KEMADRIN
Registration Number:	1350257	
Registration Number:	1621988	MANTADIL
Registration Number:	1808767	MENEST
Registration Number:	1101912	NUCOFED
Registration Number:	1498288	PEDIOTIC
Registration Number:	2713701	POLYMATRIX
Registration Number:	0806889	PROLOPRIM
Registration Number:	0735573	QUIBRON

OP \$415.00 2029430

Registration Number:	0904178	SEPTRA
Registration Number:	1216341	THALITONE
Registration Number:	1018684	VIROPTIC

CORRESPONDENCE DATA

Fax Number: (800)494-7512
Correspondence will be sent via US Mail when the fax attempt is unsuccessful.
Phone: (202) 370-4761
Email: ecallahan@nationalcorp.com
Correspondent Name: Elspeth Callahan
Address Line 1: 1100 G St NW Suite 420
Address Line 2: National Corporate Research
Address Line 4: Washington, DISTRICT OF COLUMBIA 20005

ATTORNEY DOCKET NUMBER:	F126672
NAME OF SUBMITTER:	Mariee Pilkington
Signature:	/Mariee Pilkington/
Date:	05/11/2010

Total Attachments: 3
source=T.Release - Monarch Pharmaceuticals#page2.tif
source=T.Release - Monarch Pharmaceuticals#page3.tif
source=T.Release - Monarch Pharmaceuticals#page4.tif

Release of Security Interest in Trademarks

May 11, 2010

WHEREAS, King Pharmaceuticals, Inc., certain of its subsidiaries and Credit Suisse AG, Cayman Islands Branch (formerly Credit Suisse, Cayman Islands Branch) (“**Credit Suisse**”), in its capacity as Collateral Agent for the Secured Parties (as each term is defined in the GCA (as defined below)), entered into that certain Guarantee and Collateral Agreement (the “**GCA**”) dated December 29, 2008;

WHEREAS, pursuant to the GCA, Credit Suisse and Monarch Pharmaceuticals, Inc. (the “**Assignee**”) entered into that certain Trademark Security Agreement dated December 29, 2008 and recorded with the United States Patent and Trademark Office on December 30, 2008 on Reel No. 3911, Frame 0736 (the “**Trademark Security Agreement**”);

WHEREAS, under the Trademark Security Agreement, the Assignee granted to Credit Suisse a security interest in certain Trademark Collateral (as defined in the Trademark Security Agreement), including those items set forth on Schedule 1 hereto (the “**Released Trademark Collateral**”); and

WHEREAS, Credit Suisse desires to release the security interest granted by the Assignee under the Trademark Security Agreement in the Released Trademark Collateral.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Credit Suisse, as Collateral Agent for the Secured Parties, does hereby unconditionally, irrevocably and absolutely terminate, release, extinguish and forever discharge the security interest granted under the Trademark Security Agreement in the Released Trademark Collateral, together with all of the goodwill of the business connected with the use of, or symbolized by, such Released Trademark Collateral, and hereby unconditionally, irrevocably and absolutely assigns, transfers and conveys to the Assignee all right, title and interest of Credit Suisse in, to and under such Released Trademark Collateral and such goodwill granted under the Trademark Security Agreement. This Release of Security Interest in Trademarks shall be binding upon Credit Suisse’s legal representatives, assigns and successors and upon the Secured Parties. Credit Suisse also hereby authorizes, and requests, the Director of the United States Patent and Trademark Office or his delegate to record this Release of Security Interest in Trademarks against the Released Trademark Collateral.

[signature page to follow]

IN WITNESS WHEREOF, Credit Suisse has caused this Release of Security Interest in Trademarks to be duly executed by its officer thereunto duly authorized as of the day and year first above written.

CREDIT SUISSE AG, CAYMAN
ISLANDS BRANCH

By: Doreen Barr

Name: DOREEN BARR
Title: DIRECTOR

By: Vipul Dhadha

Name: VIPUL DHADDA
Title: ASSOCIATE

[signature page – Monarch trademark release]

Monarch Pharmaceuticals, Inc.

TRADEMARKS

Trademark	Registration #	Registration Date
ACCUDOSE	2029430	January 14, 1997
ACCUDOSE	3130490	August 15, 2006
CORTISPORIN	616775	November 29, 1955
CORTISPORIN TC	2365721	July 11, 2000
KEMADRIN	581264	October 20, 1953
Kidney Shape and Design	1350257	July 23, 1985
MANTADIL	1621988	November 13, 1990
MENEST	1808767	December 7, 1993
NUCOFED	1101912	September 12, 1978
PEDIOTIC	1498288	August 2, 1988
POLYMATRIX	2713701	May 6, 2003
PROLOPRIM	806889	April 12, 1966
QUIBRON	735573	August 7, 1962
SEPTRA	904178	December 15, 1970
THALITONE	1216341	November 16, 1982
VIROPTIC	1018684	August 26, 1975

TRADEMARK APPLICATIONS

None.

TRADEMARK LICENSES

Name of Agreement	Parties (Licensor/Licensee)	Date of Agreement	Subject Matter
Agreement for Purchase and Sale of Assets Relating to Neosporin and Polysporin	Glaxo-Wellcome / Monarch Pharmaceuticals, Inc.	November 14, 1997	Neosporin and Polysporin